ASR Vermogensbeheer N.V. Acquires 11,846 Shares of IQVIA Holdings Inc. $IQV

ASR Vermogensbeheer N.V. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 7.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 171,595 shares of the medical research company’s stock after acquiring an additional 11,846 shares during the quarter. ASR Vermogensbeheer N.V. owned approximately 0.10% of IQVIA worth $27,040,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after acquiring an additional 312,807 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares during the period. American Century Companies Inc. boosted its stake in shares of IQVIA by 26.8% during the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after acquiring an additional 304,258 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after acquiring an additional 40,699 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

IQVIA stock opened at $203.94 on Thursday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34. The stock has a market capitalization of $34.67 billion, a P/E ratio of 29.51, a price-to-earnings-growth ratio of 2.08 and a beta of 1.32. The stock has a fifty day moving average of $187.68 and a 200-day moving average of $167.43.

IQVIA (NYSE:IQVGet Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 EPS. IQVIA’s revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on IQV. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Evercore ISI upped their target price on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday, July 9th. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Robert W. Baird upped their target price on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Eighteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $229.64.

Check Out Our Latest Stock Report on IQV

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.